Royalty Pharma vs Teva Pharmaceutical Industries
Royalty Pharma (RPRX) and Teva Pharmaceutical Industries (TEVA) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $39.9B
- Last close
- $69.31
- 12 months
- +74.5%
- Market value
- $51.9B
- Last close
- $44.50
- 12 months
- +74.2%
At a glance
- By market value, Teva Pharmaceutical Industries ($51.9B) is about 1.3 times Royalty Pharma ($39.9B).
- Over the last 12 months Royalty Pharma's share price moved +74.5% and Teva Pharmaceutical Industries's +74.2%; against the S&P 500 that is +62.2 points and +62.0 points.
- In their last fiscal years Royalty Pharma kept 32.4% of revenue as net income and Teva Pharmaceutical Industries 8.2%.
- In the last 90 days insiders reported 0 open-market purchases at Royalty Pharma and 0 at Teva Pharmaceutical Industries; members of Congress disclosed 0 trades in Royalty Pharma and 0 in Teva Pharmaceutical Industries.
- Next results: Royalty Pharma Feb 9, 2027, Teva Pharmaceutical Industries not announced.
Share price over the last 12 months
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Royalty Pharma RPRXNASDAQ · Pharmaceutical Preparations | Teva Pharmaceutical Industries TEVANYSE · Pharmaceutical Preparations | |
|---|---|---|
| Size and profitability | ||
| Market value | $39.9B | $51.9B |
| Revenue, last fiscal year | $2.38B | $17.3B |
| Net income, last fiscal year | $771M | $1.41B |
| Net marginNet income as a share of revenue | 32.4% | 8.2% |
| Free cash flow | ||
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Common questions
How do Royalty Pharma and Teva Pharmaceutical Industries compare in size?
Teva Pharmaceutical Industries has the larger market value: Royalty Pharma $39.9B and Teva Pharmaceutical Industries $51.9B, at the last close.
Whose share price rose more over the last 12 months, RPRX or TEVA?
Over the last 12 months Royalty Pharma moved +74.5% and Teva Pharmaceutical Industries +74.2%. Past price moves say nothing about the future.
Which has had more insider buying, Royalty Pharma or Teva Pharmaceutical Industries?
Since 2006, Royalty Pharma insiders reported 18 open-market purchases against 6 for Teva Pharmaceutical Industries. These are counts of what was filed, not a view on either stock.
Do members of Congress trade RPRX or TEVA?
In the last 12 months, members of Congress disclosed 0 trades in Royalty Pharma (RPRX) and 0 in Teva Pharmaceutical Industries (TEVA).
When did insiders last buy RPRX and TEVA?
Royalty Pharma: Jun 28, 2023. Teva Pharmaceutical Industries: Sep 9, 2025.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Royalty Pharma pageTeva Pharmaceutical Industries pageRare insider trades this weekAll comparisons
https://oqro.io/compare/rprx-vs-teva